Intrinsiqq
Bio-Techne Corporation logo

Bio-Techne Corporation Financials

TECH

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 18 available years
Income Statement
JUN 2026
JUN 2025
JUN 2024
JUN 2023
JUN 2022
Revenues
Revenue$1,215$1,220$1,159$1,137$1,106
Cost of Revenue$416$429$389$367$349
Gross Profit$799$790$770$770$756
General & Administrative$452$589$466$378$373
Research & Development$95$99$97$92$87
Total Operating Expenses$547$688$563$471$460
Operating Income$252$102$207$299$297
Non-Operating
Net Interest Expense-$5-$5-$12-$8-$11
Other Non-Operating Income (Expense)-$6$1-$9$48$15
EBT (Earnings Before Tax)$241$98$186$339$301
Income Tax Expense$59$25$18$53$38
Minority Interest–––$0-$9
Net Income
Net Income$182$73$168$285$272
Per Share Data
Revenue Per Share$7.74$7.64$7.21$7.02$6.74
EPS (Basic)$1.17$0.47$1.07$1.81$1.73
EPS (Diluted)$1.16$0.46$1.05$1.76$1.66
Weighted Avg Shares (Basic)156.0M157.5M157.7M157.2M39.2M
Weighted Avg Shares (Diluted)157.0M159.7M160.8M161.9M41.0M
Shares Outstanding157.0M159.7M160.8M161.9M164.1M
Dividends Per Share$0.32$0.32$0.32$0.32$0.31

Bio-Techne (TECH) financials: revenue, profit and margins

Bio-Techne (TECH) generated about $1.2 billion in revenue and $182 million in net income (a 15.0% net margin) over the trailing twelve months, growing at roughly 5.5% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Bio-Techne's (TECH) revenue?+

Bio-Techne generated about $1.2 billion in revenue over the trailing twelve months. Revenue has grown at roughly 5.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Bio-Techne profitable?+

Yes, Bio-Techne reported about $182 million in net income over the trailing twelve months, a net profit margin of roughly 15.0%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Bio-Techne's profit margins?+

Bio-Techne runs a gross margin of about 65.8%, an operating margin of about 20.7%, a net margin of about 15.0%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Bio-Techne growing?+

Bio-Techne's revenue has compounded at roughly 5.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside TECH's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 17 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 29 Oct 2026. How this is calculated.

Fiscal year ends Jun.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TECH

CompareIntrinsic value
BCRXBioCryst Pharmaceuticals Inc.
$8.24-3.85%64
RGENRepligen Corporation
$178.20-0.04%35
HALOHalozyme Therapeutics Inc.
$130.34+1.34%66
TARSTarsus Pharmaceuticals Inc.
$69.07-4.91%55
ADMAAdma Biologics Inc.
$10.48-5.67%82
KRYSKrystal Biotech Inc.
$310.84+1.90%44
TWSTTwist Bioscience Corporation
$142.58+1.63%40
IMCRImmunocore Holdings plc
$29.23-2.66%40

Held by ETFs

TECH is in 159 US ETFs. The largest of them, with TECH's weight in each:

Spot a number that looks wrong? Check it in TECH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TECH

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.